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Introduction {#jah31455-sec-0004}
============

Congenital heart disease (CHD) composes the largest group of congenital anomalies and affects ≈1% of births in the United States and Europe.[1](#jah31455-bib-0001){ref-type="ref"}, [2](#jah31455-bib-0002){ref-type="ref"}, [3](#jah31455-bib-0003){ref-type="ref"} CHD is a leading cause of stillbirth and infant death and accounts for 4.2% of neonatal deaths in the United States.[4](#jah31455-bib-0004){ref-type="ref"} Babies with severe CHD subtypes require complex surgeries for survival. With advances in medical, surgical, and intensive care interventions, an estimated 83% of babies with CHD now survive infancy in the United States.[5](#jah31455-bib-0005){ref-type="ref"} Although 1‐year survival estimates have been described,[3](#jah31455-bib-0003){ref-type="ref"}, [6](#jah31455-bib-0006){ref-type="ref"}, [7](#jah31455-bib-0007){ref-type="ref"}, [8](#jah31455-bib-0008){ref-type="ref"}, [9](#jah31455-bib-0009){ref-type="ref"}, [10](#jah31455-bib-0010){ref-type="ref"}, [11](#jah31455-bib-0011){ref-type="ref"} long‐term survival estimates are not well researched, and survival may continue to decrease into adulthood.

A previous systematic review of the long‐term prognosis of CHD included only hospital‐based studies that ascertained cases postsurgically or in adulthood; estimates were not representative of all persons with CHD.[12](#jah31455-bib-0012){ref-type="ref"} We conducted a systematic review and meta‐analysis of population‐based studies reporting long‐term survival of persons born with CHD. The aim was to assess and quantify long‐term survival to inform health services planning and decision making.

Methods {#jah31455-sec-0005}
=======

Search Strategy {#jah31455-sec-0006}
---------------

We conducted comprehensive literature searches of Medline, Embase, and Scopus from inception (1946, 1974, and 1996, respectively) to June 18, 2015. MeSH terms and keywords were entered systematically into the databases. The keywords included *congenital* and *heart* or *cardiac* or *cardiovascular* and subject heading searches such as "exp Heart Defects, Congenital/ep, mo" but varied according to database. The list of search terms is available from the authors.

After systematic searches of each database, the citations were extracted, and titles and abstracts were screened according to the inclusion criteria. Full articles were retrieved for all relevant citations. Reference lists of included articles were scanned and examined, and key journals were searched using keywords.

Inclusion Criteria {#jah31455-sec-0007}
------------------

Population‐based original studies were included if they (1) ascertained all persons born with CHD within a predefined geopolitical area; (2) reported survival estimates (or the number of patients born and the number or proportion alive) at age ≥5 years; (3) reported survival estimates for all CHD combined or a single CHD subtype including ventricular septal defect, pulmonary valve stenosis, atrial septal defect, aortic valve atresia or stenosis, atrioventricular septal defect, coarctation of aorta, common arterial truncus, pulmonary valve atresia (with ventricular septal defect or with intact ventricular septum), tetralogy of Fallot, total anomalous pulmonary venous return, transposition of great vessels, tricuspid atresia, single ventricle, hypoplastic left heart, and Ebstein\'s anomaly; (4) were available from the British Library or the Internet and were written in the English language.

Exclusion Criteria {#jah31455-sec-0008}
------------------

Articles were excluded if patients were not followed from birth (eg, follow‐up began in adulthood or after surgical correction); patients were not born in well‐defined regions (ie, hospital‐based); survival was not estimated as a proportion of those born with CHD (eg, age‐specific population mortality rates); survival was reported only for certain subtype groups (eg, "severe" CHD). For multiple articles reported on the same data set, the largest study or the study with the most recent study period was included. Both articles were included if they reported survival for different CHD subtypes or ages.

Data Extraction {#jah31455-sec-0009}
---------------

K.E.B. performed the literature searches, screened citations, and reviewed 40 full papers. J.R. screened 10% of the titles and all abstracts to confirm decisions about inclusion, and extracted data from all included papers. There were no discrepancies between reviewers regarding article inclusion.

Study characteristics including study design, quality, data sources, prevalence estimates, and the percentage of cases with extracardiac anomalies (ie, cases of CHD occurring with another congenital anomaly not of the cardiovascular system, such as Down syndrome or cleft lip) were extracted from each article. If it was unclear whether cases with extracardiac anomalies were included, the authors were contacted.

Kaplan--Meier survival estimates and corresponding 95% CIs were obtained from each included study at ages 1 year, 5 years, 10 years, and so forth. If 95% CIs were not reported, the authors were contacted. If this was unsuccessful, the number of patients born and the proportion that survived were used to estimate binomial 95% CIs, assuming no cases were censored. Survival estimates for all CHD subtypes combined and for each CHD subtype were extracted. If survival estimates were presented only graphically, the authors were contacted for survival estimates. If this was unsuccessful, survival estimates were extracted using Plot Digitizer software.[13](#jah31455-bib-0013){ref-type="ref"}, [14](#jah31455-bib-0014){ref-type="ref"}

Statistical Analysis {#jah31455-sec-0010}
--------------------

If there were at least 3 studies reporting survival, pooled estimates of survival were calculated using a meta‐analysis with random effects. Weighting for each article was allocated using the inverse of the variance. If the number of studies is small, the estimation of between‐study variance is thought to be imprecise in random‐effects models.[15](#jah31455-bib-0015){ref-type="ref"} Consequently, if there were only 3 studies reporting survival, the pooled survival was also estimated using fixed‐effects meta‐analysis to allow comparison. To stabilize the variance and adjust the study weights, a simplified double‐arcsine transformation was performed on the survival estimates and 95% CIs.[16](#jah31455-bib-0016){ref-type="ref"} The Cochrane Q test and the I^2^ statistic were used to test for heterogeneity in survival estimates between articles, with I^2^\>50% indicating substantial heterogeneity.[17](#jah31455-bib-0017){ref-type="ref"} Random‐effects metaregression was performed for all CHD subtypes combined to assess year of delivery as a source of heterogeneity. In this analysis, the year in which the study commenced was used as an explanatory variable. The adjusted *R* ^*2*^ value was used to estimate the proportion of between‐article variation accounted for by the year of study commencement. A bubble plot was used to present the fitted metaregression model. In this analysis, bubbles represent each article, with sizes dependent on the precision of the survival estimates. Publication bias was assessed with the Egger test.[18](#jah31455-bib-0018){ref-type="ref"}

Analysis was performed in Stata 13 (StataCorp), and *P*\<0.05 was considered statistically significant.

Quality Appraisal {#jah31455-sec-0011}
-----------------

Quality appraisal was based on 4 of the 6 domains developed by Hayden et al to assess potential bias in systematic reviews of prognostic studies.[19](#jah31455-bib-0019){ref-type="ref"} The domains used were study ascertainment, study attrition, outcome ascertainment, and analysis. The domains relating to confounding and prognostic factors were not relevant to this review because the primary aim was to investigate unadjusted survival estimates.

Results {#jah31455-sec-0012}
=======

Figure [1](#jah31455-fig-0001){ref-type="fig"} shows a Preferred Reporting Items for Systematic Reviews and Meta‐Analyses diagram for the flow of articles through the review. Of 7840 identified articles, 16 met the inclusion criteria.[20](#jah31455-bib-0020){ref-type="ref"}, [21](#jah31455-bib-0021){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}

![Preferred Reporting Items for Systematic Reviews and Meta‐Analyses diagram for the flow of articles through the review.](JAH3-5-e002846-g001){#jah31455-fig-0001}

Study Characteristics {#jah31455-sec-0013}
---------------------

All included studies were conducted in high‐income Western populations, with 10 in Europe and 6 in the United States (Table [1](#jah31455-tbl-0001){ref-type="table-wrap"}). Although several articles reported survival of subsets of the same population, all were included because survival was reported for different CHD subtypes or at different ages. The oldest article included patients born between 1973 and 1997,[22](#jah31455-bib-0022){ref-type="ref"} and the most recent article included patients born between 1991 and 2007.[35](#jah31455-bib-0035){ref-type="ref"} Of the 16 included articles, 9 included cases with extracardiac anomalies, with ≈20% of cases occurring with other congenital anomalies in each article.[23](#jah31455-bib-0023){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"} Four articles excluded patients with trisomy 13 (Patau syndrome) and 18 (Edward syndrome) only.[21](#jah31455-bib-0021){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"} Two articles excluded cases of CHD with any extracardiac anomalies,[20](#jah31455-bib-0020){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"} and 1 did not state whether cases with extracardiac anomalies were included.[31](#jah31455-bib-0031){ref-type="ref"} Prevalence estimates were reported by most studies and ranged from 3.7[30](#jah31455-bib-0030){ref-type="ref"} to 10.2[26](#jah31455-bib-0026){ref-type="ref"} per 1000 live births when considering all CHD as a composite group.

###### 

Descriptions of the Included Articles

  Study                                                           Included Birth Years   Study Location                                                                                                                                                                                 Included CHD Subtypes (ICD Codes)                                                                                       Inclusion of ECAs                                                                                                             Age Limit for Diagnosis                                       Source of Cases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Source of Death Information                                                                                                                         Percentage of Traced Cases                                Prevalence per 1000 Live Births
  --------------------------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ---------------------------------
  Dastgiri et al[20](#jah31455-bib-0020){ref-type="ref"}          1980--1997             Glasgow, Scotland                                                                                                                                                                              All CHD subtypes (ICD 10: Q20--26)                                                                                      Author\'s response: excluded                                                                                                  No age limit                                                  Glasgow register of Congenital Anomalies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Registrar General for Scotland                                                                                                                      97% (all congenital anomalies)                            Not stated
  Fixler et al[21](#jah31455-bib-0021){ref-type="ref"}            1996--2003             Texas, USA                                                                                                                                                                                     SV physiology: HLH (ICD 9: 746.7), PVA‐IVS (746.0), SV (745.3), TA (746.1), d‐TGV (745.1)                               Cases with trisomy 13 or 18 were excluded; 14.1% of HLH, 21.0% of SV, 15.3% of PVA‐IVS, 17.9% of TA, 9.3% of d‐TGV had ECAs   1 year                                                        Texas Birth Defects Registry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Medical records, death certificates, national death index                                                                                           N/A, nontraced cases considered alive                     Not stated
  Frid et al[22](#jah31455-bib-0022){ref-type="ref"}              1973--1997             Sweden                                                                                                                                                                                         AVSD (ICD 9: 745G, ICD 10: 21.2)                                                                                        Cases with trisomy 13 or 18 were excluded; 68.9% had trisomy 21                                                               None stated                                                   Register of Congenital Malformations, Register of Congenital Heart Malformations, and the Medical Birth Register; local registries at 4 pediatric cardiology centers were also searched for the beginning of the study period                                                                                                                                                                                                                                                                                                                                              National population database and medical records                                                                                                    98.7% of all cases with AVSD                              0.3
  Garne[23](#jah31455-bib-0023){ref-type="ref"}                   1986--1998             Funen County, Denmark                                                                                                                                                                          All CHD subtypes (EUROCAT criteria ie, ICD 10: Q20--26)                                                                 Cases with ECAs were included, 21% of cases                                                                                   5 years and diagnosed before 2002                             EUROCAT Registry of Congenital Malformations for Funen County                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              National registration system                                                                                                                        99.6%                                                     7.9
  Idorn et al[24](#jah31455-bib-0024){ref-type="ref"}             1977--2009             Denmark, Europe                                                                                                                                                                                HLH (ICD 10: Q234), PVA‐IVS (Q220), TA (Q224)                                                                           Cases with ECAs were included, 10% of cases                                                                                   All ages                                                      Danish register of congenital heart disease, local surgical registries, medical records, local fetal ultrasound registries                                                                                                                                                                                                                                                                                                                                                                                                                                                 Civil registration system                                                                                                                           Not stated                                                0.4
  Jackson et al[25](#jah31455-bib-0025){ref-type="ref"}           1979--1988             Merseyside, England                                                                                                                                                                            All CHD subtypes (ICD 9: 745.00--747.49)                                                                                Cases with ECAs were included, percentage not stated                                                                          No age limit                                                  Liverpool Registry of Congenital Malformations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Liverpool Registry of Congenital Malformations and hospital records                                                                                 Not stated                                                7.6
  Meberg et al[26](#jah31455-bib-0026){ref-type="ref"}            1982--1996             Vestfold, Norway, Europe                                                                                                                                                                       All CHD subtypes (no ICD codes stated)                                                                                  Cases with ECAs were included, 20% of cases                                                                                   None stated                                                   Vestfold County Central Hospital, regional cardiology services, Child Health Centers and pediatric departments of the hospitals in neighboring counties                                                                                                                                                                                                                                                                                                                                                                                                                    Hospital records                                                                                                                                    100%                                                      10.2
  Miller et al[27](#jah31455-bib-0027){ref-type="ref"}            1979--2003             Metropolitan Atlanta, GA, USA                                                                                                                                                                  AVSD (ICD 9: 745.000--747.999)                                                                                          Cases with trisomy 13 or 18 were excluded, 52.4% had trisomy 21                                                               None stated                                                   Metropolitan Atlanta Congenital Defects Program                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Hospital records and vital records from the state of Georgia, National Death Index                                                                  Not stated but number of untraced "assumed to be small"   Not stated
  Moons et al[28](#jah31455-bib-0028){ref-type="ref"}             2002                   Belgium                                                                                                                                                                                        All CHD subtypes (no ICD codes specified)                                                                               Author response: cases with ECAs were included, percentage not stated                                                         5 years                                                       Pediatric cardiology database covering 7 tertiary care centers in Belgium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Medical records                                                                                                                                     Not stated                                                8.3
  Nembhard et al[29](#jah31455-bib-0029){ref-type="ref"}          1996--2003             Texas, USA                                                                                                                                                                                     ICD 9 (746--747)                                                                                                        Cases with trisomy 13 or 18 were excluded, 20.7% of cases had ECAs                                                            1 year                                                        Texas birth defects register                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Death certificates linked to the Texas birth defects register                                                                                       Not stated                                                8.7
  Olsen et al[30](#jah31455-bib-0030){ref-type="ref"}             1977--2006             Denmark                                                                                                                                                                                        All CHD subtypes: ICD 8: 746 to 747 (except 746.7 and 747.5--747.9) and ICD‐10: Q20--Q26 (except Q26.5--Q26.6)          Cases with ECAs were included, 20.0% of cases                                                                                 1 year                                                        Danish National Registry of Patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Civil registration system                                                                                                                           100%                                                      3.7
  Samanek and Voriskova[31](#jah31455-bib-0031){ref-type="ref"}   1980--1990             Bohemia, Czech Republic                                                                                                                                                                        All CHD subtypes (no ICD codes specified)                                                                               Not stated                                                                                                                    None stated                                                   Hospital records                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Autopsy reports                                                                                                                                     Not stated                                                6.2
  Tennant et al[32](#jah31455-bib-0032){ref-type="ref"}           1985--2003             Northeast England                                                                                                                                                                              All CHD subtypes (ICD 10: Q20--26)                                                                                      Cases with ECAs were excluded, percentage not stated                                                                          16 years of age (1985--2001) or, from 2001, to age 12 years   Northern Congenital Abnormality Survey                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Office for National Statistics death registrations                                                                                                  99% (of all congenital anomalies)                         6.8
  Wang et al (2011)[33](#jah31455-bib-0033){ref-type="ref"}       1983--2006             New York State, USA                                                                                                                                                                            TGV (ICD 9: 745.10--745.12, 745.19), ToF (745.2), HLH (746.7), AVA/S (746.3), CAT (745.0), AVSD (745.6), CoA (747.10)   Cases with ECAs were included, percentage not stated                                                                          None stated                                                   Congenital Malformations Registry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Death certificates files maintained by the New York State Department of Health                                                                      97% (of all congenital anomalies)                         9.5
  Wang et al (2013)[34](#jah31455-bib-0034){ref-type="ref"}       1983--2006             New York State, USA                                                                                                                                                                            TGV (ICD 9: 745.10--745.12, 745.19), ToF (745.2), HLH (746.7), CoA (747.10)                                             Cases with ECAs were included, percentage not stated                                                                          2 years                                                       Congenital Malformations Registry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Death certificate files maintained by the New York State Department of Health                                                                       Not stated                                                Not stated
  Wang et al (2015)[35](#jah31455-bib-0035){ref-type="ref"}       1991--2007             Arizona, Colorado, Florida, Georgia (5 counties of Metropolitan Atlanta), Illinois, Massachusetts, Michigan, Nebraska, New Jersey, New York (excluding New York City), North Carolina, Texas   TGV (ICD 9: 745.10--745.12, 745.19), ToF (745.2), HLH (746.7), AVA/S (746.3), CAT (745.0), AVSD (745.6), CoA (747.10)   Cases with ECAs included, percentage not stated                                                                               None stated                                                   Arizona Birth Defects Monitoring Program, Metropolitan Atlanta Congenital Defects Program, Colorado Responds to Children with Special Needs, Florida Birth Defects Registry, Illinois Adverse Pregnancy Outcomes Reporting System, Massachusetts Birth Defects Monitoring Program, Michigan Birth Defects Registry, Nebraska Birth Defects Registry, New Jersey Special Child Health Services Registry, New York State Congenital Malformations Registry, North Carolina Birth Defects Monitoring Program, and Texas Birth Defects Epidemiology, and Surveillance Branch   Death certificates, hospital discharge files (Arizona, Texas), medical records (Arizona, Texas), and the National Death Index (Georgia, Michigan)   Not stated                                                2.1

AVA/S, aortic valve atresia or stenosis; AVSD, atrioventricular septal defect; CAT, common arterial truncus; CHD, congenital heart disease; CoA, coarctation of aorta; d‐TGV, dextro‐TGV; ECA, extracardiac anomaly; HLH, hypoplastic left heart; ICD, International Classification of Disease; IVS, intact ventricular septum; N/A, not available; PVA, pulmonary valve atresia (with ventricular septal defect or IVS); SV, single ventricle; TA, tricuspid atresia; TGV, transposition of great vessels; ToF, tetralogy of Fallot.
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Survival Estimates {#jah31455-sec-0014}
------------------

Survival was reported to age 5 years in 5 articles,[20](#jah31455-bib-0020){ref-type="ref"}, [21](#jah31455-bib-0021){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"} to age 8 years in 1 article,[35](#jah31455-bib-0035){ref-type="ref"} to age 10 years in 3 articles,[25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"} to age 15 years in 2 articles,[22](#jah31455-bib-0022){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"} to age 20 years in 1 article,[32](#jah31455-bib-0032){ref-type="ref"} to age 25 years in 3 articles,[30](#jah31455-bib-0030){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"} and to age 30 years in 1 article.[24](#jah31455-bib-0024){ref-type="ref"}

For all CHD (as a composite group), pooled 1‐year survival from 6 articles was 87.0% (95% CI 82.1--91.2), pooled 5‐year survival from 8 articles was 85.4% (95% CI 79.4--90.5), and pooled 10‐year survival from 4 articles was 81.4% (95% CI 73.8--87.9) (Figure [2](#jah31455-fig-0002){ref-type="fig"}). It was not possible to pool estimates beyond 10 years because there were too few articles; however, Figure [3](#jah31455-fig-0003){ref-type="fig"} shows the survival estimates plotted over increasing age, up to age 25 years. The fitted metaregression showed that survival decreases very gradually with increasing age over 25 years. There was no evidence of publication bias according to Egger tests (*P*=0.748 for 1 year, *P*=0.237 for 5 years, and *P*=0.601 for 10 years). There was significant heterogeneity between articles for survival at 1 year (I^2^=99.0%, *P*\<0.001), 5 years (I^2^=99.6%, *P*\<0.001), and 10 years (I^2^=99.5%, *P*\<0.001). Metaregression showed that a more recent study period was significantly associated with increased 1‐, 5‐, and 10‐year survival (*P*=0.047, *P*=0.013, and *P*=0.046, respectively) (Figure [4](#jah31455-fig-0004){ref-type="fig"}). According to the adjusted *R* ^2^ values, study period accounted for 50.9%, 62.8%, and 87.0% of the between‐article variance for 1‐, 5‐, and 10‐year survival. After adjustment for study period, however, substantial residual heterogeneity remained that was attributable to between‐study heterogeneity (I^2^=98.2% at age 1 year, I^2^=98.4% for survival at age 5 years, and I^2^=93.7% for survival at age 10 years).

![Forest plot for all congenital heart disease at ages 1, 5, and 10 years.](JAH3-5-e002846-g002){#jah31455-fig-0002}

![Bubble plot of survival estimates for all congenital heart disease at ages 1 to 25 years.](JAH3-5-e002846-g003){#jah31455-fig-0003}

![Bubble plots showing the association between study period and survival for all congenital heart disease. A, 1‐year survival. B, 5‐year survival. C, 10‐year survival.](JAH3-5-e002846-g004){#jah31455-fig-0004}

Table [2](#jah31455-tbl-0002){ref-type="table-wrap"} shows the survival estimates and pooled survival estimates for persons with CHD by subtype. Pooled 1‐year survival was lowest for those with hypoplastic left heart (17.4%, 95% CI 0.0--54.5) and greatest for those with ventricular septal defect (95.5%, 95% CI 89.0--99.2). There was significant heterogeneity of survival estimates among articles for all CHD subtypes, with the exception of tetralogy of Fallot (I^2^=0%, *P*=0.169). Heterogeneity of estimates for single ventricle was of borderline statistical significance (I^2^=65.0%, *P*=0.057). Pooled 5‐year survival varied by subtype, with survival for hypoplastic left heart at 12.5% (95% CI 0.0--41.4) and survival for ventricular septal defect at 97.7% (95% CI 93.5--99.8). With the exception of tetralogy of Fallot (I^2^=0.0%, *P*=0.957) and single ventricle (I^2^=26.9%, *P*=0.250), there was significant heterogeneity of survival estimates among articles (Table [2](#jah31455-tbl-0002){ref-type="table-wrap"}). It was possible to calculate pooled 15‐year survival estimates for aortic valve atresia or stenosis, atrioventricular septal defect, common arterial truncus, and coarctation of aorta but not for any other CHD subtypes. There were too few studies to calculate pooled survival beyond age 15 years, although in the few studies that reported survival into adulthood, survival was still gradually declining.

###### 

Survival Estimates at Age One to 25

  Subtype                                   Article              N                                                          Survival Estimates (95% CI)                                                                                                                                                                                                                                                                               
  ----------------------------------------- -------------------- ---------------------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- --
  All congenital heart disease              Dastgiri et al^20^   1069                                                       78.4 (75.8--80.8)[a](#jah31455-note-0102){ref-type="fn"}     74.7 (73.8--75.5)[b](#jah31455-note-0103){ref-type="fn"}                                                                                                                                                                                     
  Jackson et al^25^                         1543                 86.1 (84.3--87.8)[a](#jah31455-note-0102){ref-type="fn"}   82.0 (81.0--83.0)                                            80.4 (79.5--81.7)[b](#jah31455-note-0103){ref-type="fn"}                                                                                                                                                                                     
  Meberg et al^26^                          360                  91.4 (88.0--94.1)[a](#jah31455-note-0102){ref-type="fn"}   88.9 (85.2--91.9)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Moons et al^28^                           921                  96.0 (94.5--97.2)[a](#jah31455-note-0102){ref-type="fn"}   95.6 (94.0--96.8)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Nembhard et al^29^                        19 530                                                                          90.7 (90.2--91.1)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Olsen et al^30^                           6646                 80 (79--81)                                                76 (75--77)[a](#jah31455-note-0102){ref-type="fn"}           75 (74--76)                                                                                                                                                                       72 (70--73)                                                
  Samanek et al^31^                         5030                 80.0 (78.9--81.1)                                          77.8 (76.6--79.0)                                            77.4 (76.2--78.5)                                           77.1 (75.9--78.3)                                                                                                                                                                
  Tennant et al^32^                         4281                 92.3 (91.5--93.1)                                          91.1 (90.2--91.9)                                            90.8 (89.9--91.6)                                           90.3 (89.3--91.2)                                          89.5 (88.4--90.6)                                                                                                     
  Pooled estimate (95% CI)                  87.0 (82.1--91.2)    85.4 (79.4--90.5)                                          81.4 (73.8--87.9)                                                                                                                                                                                                                                                                                         
  Heterogeneity I^2^ & *P*--value           99.0%, *P*\<0.001    99.6%, *P*\<0.001                                          99.5%, *P*\<0.001                                                                                                                                                                                                                                                                                         
  Ventricular septal defect                 Garne^23^            195                                                                                                                     96.9 (93.4, 98.9)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                     
  Moons et al^28^                           303                                                                             99.3 (97.6--99.9)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Nembhard et al^29^                        10 382                                                                          93.9 (93.5--94.4)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Olsen et al^30^                           1559                 94 (93--95)                                                                                                             90 (89--91.7)                                                                                                                                                                                                                                
  Samanek et al^31^                         2092                 91.1 (89.8--92.3)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                            89.4 (88.0--90.7)                                                                                                                                                                
  Tennant et al^32^                         1805                 99.2 (98.7--99.5)                                          99.1 (98.6--99.5)                                            99.1 (98.5--99.4)                                           99.1 (98.5--99.4)                                          98.3 (96.6--99.1)                                                                                                     
  Pooled estimate (95% CI)                  95.5 (89.0--99.2)    97.7 (93.5--99.8)                                                                                                                                                                                                                                                                                                                                                    
  *95.5 (95.0*--*96.0)*                                                                                                                                                                                                                                                                                                                                                                                                               
  Heterogeneity I^2^ & *P*‐value            99.0%, *P*\<0.001    98.1%, *P*\<0.001                                                                                                                                                                                                                                                                                                                                                    
  Pulmonary valve stenosis                  Garne ^23^           33                                                                                                                      97.0 (84.2--99.9)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                     
  Nembhard et al^29^                        1170                                                                            91.6 (89.9--93.1)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Samanek et al^31^                         292                  96.2 (94.0--98.5)                                          95.6 (93.1--98.0)                                            95.6 (93.1--98.0)                                           95.6 (93.1--98.0)                                                                                                                                                                
  Tennant et al^32^                         382                  98.7 (96.8--99.5)                                          98.1 (96.1--99.1)                                            98.1 (96.1--99.1)                                           98.1 (96.1--99.1)                                          98.1 (96.1--99.1)                                                                                                     
  Pooled estimate (95% CI)                                       95.6 (91.1--98.6)                                                                                                                                                                                                                                                                                                                                                    
  Heterogeneity I^2^ & *P*‐value                                 89.6%, *P*\<0.001                                                                                                                                                                                                                                                                                                                                                    
  Atrial septal defect                      Garne^23^            78                                                                                                                      98.7 (93.1, 100.0)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                    
  Moons et al^28^                           162                                                                             99.4 (96.6--100.0)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                 
  Nembhard et al^29^                        9164                                                                            89.9 (89.3--90.5)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Olsen et al^30^                           361                  93 (90--95.3)                                                                                                           91 (88--95.6)                                                                                                                                                                     84 (72--91)                                                
  Samanek et al^31^                         436                  94.0 (92.4--96.3)                                                                                                       92.9 (90.1--95.1)[a](#jah31455-note-0102){ref-type="fn"}    92.9 (90.1--95.1)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                         
  Tennant et al^32^                         365                  97.3 (95.0--98.5)                                          97.0 (94.6--98.3)                                            97.0 (94.6--98.3)                                           96.3 (93.3--98.0)                                          96.3 (93.3--98.0)                                                                                                     
  Pooled estimate (95% CI)                  94.9 (92--97.2)      96.8 (90.8--99.7)                                          94.0 (89.9--97.1)                                                                                                                                                                                                                                                                                         
  *94.8 (93.5*--*96.0)*                     95.4%, *P*\<0.001    *94.3 (92.7*--*95.6)*                                                                                                                                                                                                                                                                                                                                                
  Heterogeneity I^2^ & *P*‐value            77.4%, *P*\<0.001                                                               81.6%, *P*=0.004                                                                                                                                                                                                                                                                                          
  Aortic valve atresia/stenosis             Garne^23^            24                                                                                                                      87.5 (67.6, 97.3)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                     
  Moons et al^28^                           36                                                                              100.0 (90.3--100.0)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                
  Samanek^31^                               391                  90.3 (87.3--93.3)                                                                                                                                                                   88.4 (85.1--91.7)                                                                                                                                                                
  Tennant et al^32^                         171                  92.4 (87.3--95.5)                                          91.2 (85.9--94.6)                                            91.2 (85.9--94.6)                                           89.3 (83.2--3.3)                                           89.3 (83.2--3.3)                                                                                                      
  Wang et al^33^                            877                                                                                                                                                                                                      74.1 (71.0--77.0)                                                                                                     73.4 (70.1--76.4)                                          
  Wang et al^35^                            2646                 83.6 (82.1--84.9)                                          81.5 (79.7--83.2)                                                                                                                                                                                                                                                                                         
  Pooled estimate (95% CI)                  88.7 (82.4--93.8)    92.1 (81.3--98.4)                                                                                                       84.4 (73.1--93.1)                                                                                                                                                                                                                            
  *85.0 (83.7*--*86.2)*                     92.7%, *P*\<0.001                                                               *82.2 (80.3*--*84.0)*                                                                                                                                                                                                                                                                                     
  Heterogeneity I^2^ & *P*‐value            91.3%, *P*\<0.001                                                                                                                            96.8%, *P*\<0.001                                                                                                                                                                                                                            
  Atrioventricular septal defect            Frid et al^22^       502                                                        77.1 (73.2--80.7)[a](#jah31455-note-0102){ref-type="fn"}     66.5 (62.2--70.7)[a](#jah31455-note-0102){ref-type="fn"}    64.3 (59.9--68.5)[a](#jah31455-note-0102){ref-type="fn"}   63.1 (58.8--67.4)[a](#jah31455-note-0102){ref-type="fn"}                                                              
  Garne^23^                                 20                                                                              50 (27.2--72.8)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                    
  Miller et al^27^                          338                                                                                                                                          57.9 (49.7--65.3)                                                                                                                                                                                                                            
  Moons et al^28^                           37                                                                              91.9 (78.1--98.3)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Olsen et al^30^                           354                  75 (70--79)                                                                                                             65 (59--70)                                                                                                                                                                       59 (51--65)                                                
  Samanek et al^31^                         201                  62.2 (55.4--69.0)                                          54.7 (47.7--61.8)                                            54.2 (47.1--61.2)                                           54.2 (47.1--61.2)                                                                                                                                                                
  Tennant et al^32^                         94                   84.0 (74.9--90.1)                                          80.9 (71.3--87.5)                                            79.7 (70.1--86.6)                                           79.7 (70.1--86.6)                                          79.7 (70.1--86.6)                                                                                                     
  Wang et al^33^                            1004                                                                                                                                                                                                     59.5 (56.3--62.6)                                          58.1 (56.5--61.4)                                          56.6 (52.8--60.2)                                          
  Wang et al^34^                            4884                 80.1 (79.0--81.2)                                          76.7 (75.3--78.1)                                                                                                                                                                                                                                                                                         
  Pooled estimate (95% CI)                  75.9 (70.5--81.0)    71.2 (61.9--79.6)                                          64.0 (57.2--70.5)                                            63.4 (56.3--70.3)                                                                                                                                                                                                                            
  Heterogeneity I^2^ & *P*‐value            89.0%, *P*\<0.001    92.7%, *P*\<0.001                                          81.4%, *P*\<0.001                                            85.9%, *P*\<0.001                                                                                                                                                                                                                            
  Coarctation of aorta                      Garne^23^            12                                                                                                                      58.3 (27.7--84.8)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                     
  Moons et al^28^                           46                                                                              91.3 (79.2--97.6)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Nembhard et al^29^                        1145                                                                            78.6 (76.1--80.9)                                                                                                                                                                                                                                                                                         
  Olsen et al^30^                           334                  84 (79--87)                                                                                                             82 (77--85)                                                                                                                                                                       78 (61--82)                                                
  Samanek et al^31^                         266                  68.0 (62.3--73.8)                                          65.4 (59.6--71.3)                                            65.0 (59.2--70.9)                                           65.0 (59.2--70.8)                                                                                                                                                                
  Tennant et al^32^                         189                  91.5 (86.6--94.7)                                          91.5 (86.6--94.7)                                            90.9 (85.8--94.3)                                           90.9 (85.8--94.3)                                          89.6 (83.7--93.5)                                                                                                     
  Wang et al^33^                            2529                 79.4 (77.8--81.0)                                          77.0 (75.4--78.6)                                                                                                        76.0 (74.3--77.7)                                                                                                     75.2 (73.3--77.0)                                          
  Wang et al^34^                            6365                 84.5 (83.6--85.4)                                          81.9 (80.7--83.0)                                                                                                                                                                                                                                                                                         
  Pooled estimate (95% CI)                  82.7 (75.4--89.0)    81.0 (70.7--89.4)                                          80.3 (65.0--92.0)                                            78.2 (65.9--88.4)                                                                                                                                                                                                                            
                                                                 *79.5 (76.6--82.2)*                                        *76.2 (74.6--77.7)*                                                                                                                                                                                                                                                                                       
  Heterogeneity I^2^ & *P*‐value            93.7%, *P*\<0.001    93.0%, *P*\<0.001                                          87.3%, *P*\<0.001                                            95.6%, *P*\<0.001                                                                                                                                                                                                                            
  Common arterial trunk                     Moons et al^28^      7                                                                                                                       85.7 (42.1--99.6)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                     
  Olsen et al^30^                           78                   45 (34--55)                                                45 (34--55)                                                  45 (34--55)                                                 45 (34--55)                                                45 (34--55)                                                45(34--55)                                                 
  Samanek et al^31^                         55                   12.7 (3.7--21.7)                                           10.5 (4.1--22.2)[a](#jah31455-note-0102){ref-type="fn"}      7.3 (0--15.4)                                               7.3 (0--15.4)                                                                                                                                                                    
  Tennant et al^32^                         36                   36.1 (21.0--51.4)                                          36.1 (21.0--51.4)                                            36.1 (21.0--51.4)                                                                                                                                                                                                                            
  Wang et al^33^                            460                                                                                                                                                                                                      59.2 (54.4--63.6)                                                                                                     55.2 (49.5--60.5)                                          
  Wang et al^35^                            956                  75.1 (72.7--77.7)                                                                                                                                                                                                                                                                                                                                                    
  Pooled estimate (95% CI)                  41.8 (14.1--72.6)    47.4 (21.8--73.8)                                          28.9 (16.3--43.3)                                            36.5 (14.6--62)                                                                                                                                                                                                                              
                                                                 *35.4 (30.0*--*41.0)*                                      *54.4(50.2*--*58.6)*                                                                                                                                                                                                                                                                                      
  Heterogeneity I^2^ & *P*‐value            97.6%, *P*\<0.001    96.3%, *P*\<0.001                                          87.3%, *P*\<0.001                                            94.5%, *P*\<0.001                                                                                                                                                                                                                            
  Pulmonary valve atresia (with IVS)        Fixler et al^21^     118                                                        59.3 (49.9--67.6)                                            55.7 (45.8--64.4)                                                                                                                                                                                                                            
  Idorn et al^24^                           75                   41.7 (30.1--53.3)[a](#jah31455-note-0102){ref-type="fn"}   37.5 (26.4--49.2)[a](#jah31455-note-0102){ref-type="fn"}     35.3 (24.0--46.5)[a](#jah31455-note-0102){ref-type="fn"}    37.5 (26.4--49.2)[a](#jah31455-note-0102){ref-type="fn"}   35.3 (24.0--46.5)[a](#jah31455-note-0102){ref-type="fn"}   37.5 (26.4--49.2)[a](#jah31455-note-0102){ref-type="fn"}   
  Moons et al^28^                           6                                                                               83.3 (36.5--99.1)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Samanek et al^31^                         53                   18.9 (8.1--29.6)                                           7.6 (0.3--14.8)                                              7.6 (0.3--14.8)                                             7.6 (0.3--14.8)                                                                                                                                                                  
  Pooled estimate (95% CI)                  39.7 (18.5--63.3)    41.1 (17.2--67.6)                                                                                                                                                                                                                                                                                                                                                    
  *45.5 (39.2*--*52.0)*                                                                                                                                                                                                                                                                                                                                                                                                               
  Heterogeneity I^2^ & *P*‐value            92.1%, *P*\<0.001    92.0%, *P*\<0.001                                                                                                                                                                                                                                                                                                                                                    
  Pulmonary atresia                         Garne et al^23^      5                                                                                                                       60.0 (14.7--94.7)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                     
  Pulmonary valve atresia (with VSD)        Moons et al^28^      6                                                          67 (19--96)[a](#jah31455-note-0102){ref-type="fn"}           50 (11.8--88.2)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                       
  Samanek et al^31^                         55                   61.8 (48.7--74.9)                                          54.5 (41.1--68.0)                                            45.2 (30.8--59.6)                                           45.2 (30.8--59.6)                                                                                                                                                                
  Tetralogy of Fallot                       Garne^23^            7                                                                                                                       82.6 (61.2--95.0)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                     
  Moons et al^28^                           52                   83 (70--92)[a](#jah31455-note-0102){ref-type="fn"}         82.7 (69.7--91.8)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Olsen et al^30^                           381                  83 (79--87)                                                                                                             70 (65--74)                                                                                                                                                                       67 (58--74)                                                
  Samanek et al^31^                         169                  84.6 (79.0--90.2)                                                                                                       76.6 (70.1--83.2)                                           76.6 (70.1--83.2)                                                                                                                                                                
  Tennant et al^32^                         190                  90.5 (85.4--93.9)                                          83.7 (77.6--88.2)                                            83.1 (76.9--87.7)                                           83.1 (76.9--87.7)                                          80.8 (72.8--86.6)                                                                                                     
  Wang et al^34^                            5208                 87.1 (86.1--87.9)                                          84.7 (83.5--85.8)                                                                                                                                                                                                                                                                                         
  Wang et al^34^                            1739                                                                                                                                                                                                                                                                                                                           86.9 (85.3--88.4)                                          
  Pooled estimate (95% CI)                  86.3 (83.7--88.6)    84.6 (83.5--85.7)                                          81.4 (77.5--85)                                                                                                                                                                                                                                                                                           
                                                                 *81.6 (78.6*--*84.4)*                                                                                                                                                                                                                                                                                                                                                
  Heterogeneity I^2^ & *P*‐value            0.0%, *P*=0.097      0.0%, *P*=0.957                                            36.1%, *P*=0.209                                                                                                                                                                                                                                                                                          
  Total anomalous pulmonary venous return   Garne^23^            5                                                                                                                       20 (0.5--71.6)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                        
  Samanek et al^31^                         40                   52.5 (36.7--8.23)                                          50.0 (34.2--65.8)                                            50.0 (34.2--65.8)                                           50.0 (34.2--65.8)                                                                                                                                                                
  Tennant et al^32^                         54                   72.2 (58.2--82.2)                                          72.2 (58.2--82.2)                                            72.2 (58.2--82.2)                                           72.2 (58.2--82.2)                                          72.2 (58.2--82.2)                                                                                                     
  Pooled estimate (95% CI)                                       53.7 (30--76.6)                                                                                                                                                                                                                                                                                                                                                      
                                            61.2 (51.2--70.6)                                                                                                                                                                                                                                                                                                                                                                         
  Heterogeneity I^2^ & *P*‐value                                 76.6%, *P*=0.014                                                                                                                                                                                                                                                                                                                                                     
  Transposition of the great vessels        Garne^23^            21                                                                                                                      76.2 (52.8, 91.8)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                     
  Moons et al^28^                           29                                                                              100.0 (88.1--100.0)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                
  Olsen et al^30^                           461                  74 (70--78)                                                                                                             62 (38--67)                                                                                                                                                                       50 (41--59)                                                
  Samanek et al^31^                         271                  61.6 (56.7--67.5)                                          56.5 (50.3--62.4)[a](#jah31455-note-0102){ref-type="fn"}     53.9 (46.8--60.9)                                           53.9 (46.8--60.9)                                                                                                                                                                
  Tennant et al^32^                         189                  82.5 (76.3--87.3)                                          81.0 (74.6--85.9)                                            80.3 (73.8--85.3)                                           78.4 (71.6--83.9)                                          74.1 (64.4--81.5)                                                                                                     
  Wang et al^34^                            1840                                                                                                                                                                                                                                                                                                                           74.5 (72.4--76.4)                                          
  Wang et al^34^                            4330                 83.7 (82.6--84.4)                                          81.1 (79.7--82.4)                                                                                                                                                                                                                                                                                         
  Pooled estimate (95% CI)                  76.0 (65.5--85.1)    81.9 (68.9--91.9)                                          66.1 (46.0--83.5)                                                                                                                                                                                                                                                                                         
                                                                 *67.1 (62.5*--*71.5)*                                                                                                                                                                                                                                                                                                                                                
  Heterogeneity I^2^ & *P*‐value            96.9%, *P*\<0.001    95.9%, *P*\<0.001                                          93.6%, *P*\<0.001                                                                                                                                                                                                                                                                                         
  Tricuspid atresia                         Fixler et al^21^     67                                                         76.1 (64.0--84.6)                                            74.6 (62.4--83.4)                                                                                                                                                                                                                            
  Idorn et al^24^                           106                  68.0 (58.2--76.7)[a](#jah31455-note-0102){ref-type="fn"}   61.7 (51.4--70.6)[a](#jah31455-note-0102){ref-type="fn"}     60.5 (50.4--69.7)[a](#jah31455-note-0102){ref-type="fn"}    57.4 (47.6--67.1)[a](#jah31455-note-0102){ref-type="fn"}   57.4 (47.6--67.1)[a](#jah31455-note-0102){ref-type="fn"}   57.4 (47.6--67.1)[a](#jah31455-note-0102){ref-type="fn"}   
  Moons et al^28^                           4                    100 (39.8--100.0)[a](#jah31455-note-0102){ref-type="fn"}   100 (39.8--100.0)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Samanek et al^31^                         39                   46.2 (30.2--62.1)                                                                                                       35.9 (20.5--51.3)                                           35.9 (20.5--51.3)                                                                                                                                                                
  Tennant et al^32^                         24                   83.3 (61.5--93.4)                                          66.7 (44.3--81.7)                                            62.5 (40.3--78.4)                                           62.5 (40.3--78.4)                                                                                                                                                                
  Pooled estimate (95% CI)                  71.4 (57.2--83.7)    53.7 (30.0--76.6)                                          53.1 (36.5--69.2)                                            53.3 (37.2--69.1)                                                                                                                                                                                                                            
                                                                 *55.1 (47.3*--*62.9)*                                      *56.2 (49.1*--*63.1)*                                                                                                                                                                                                                                                                                     
  Heterogeneity I^2^ & *P*‐value            74.4%, *P*=0.004     93.9%, *P*\<0.001                                          72.4%, *P*=0.027                                             72.9%, *P*=0.025                                                                                                                                                                                                                             
  Hypoplastic left heart                    Garne                22                                                                                                                      4.5 (0.1--22.8)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                       
  Idorn et al^24^                           252                  12.5 (8.9--17.5)[a](#jah31455-note-0102){ref-type="fn"}    10.4 (6.9--14.8)[a](#jah31455-note-0102){ref-type="fn"}      10.4 (6.9--14.8)[a](#jah31455-note-0102){ref-type="fn"}     8.8 (5.6--12.9)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                           
  Moons et al^28^                           10                   50 (18.7--81.3)[a](#jah31455-note-0102){ref-type="fn"}     40.0 (12.2--73.8)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Samanek et al^31^                         172                  0 (0.0--2.1)[a](#jah31455-note-0102){ref-type="fn"}        0 (0.0--2.1)[a](#jah31455-note-0102){ref-type="fn"}          0 (0.0--2.1)[a](#jah31455-note-0102){ref-type="fn"}         0 (0.0--2.1)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                              
  Tennant et al^32^                         73                   4.1 (1.1--10.5)                                            2.9 (0.5--8.9)                                                                                                                                                                                                                                                                                            
  Wang et al^34^                                                                                                                                                                                                                                                                                                                                                           33.1 (30.6--35.7)                                          
  Wang et al^34^                            2976                 55.2 (53.4--56.9)                                          50.6 (48.4--52.7)                                                                                                                                                                                                                                                                                         
  Pooled estimate (95% CI)                  17.4 (0.0--54.5)     12.5 (0.0--41.4)                                                                                                                                                                                                                                                                                                                                                     
  Heterogeneity I^2^ & *P*‐value            99.5%, *P*\<0.001    99.1%, *P*=0.036                                                                                                                                                                                                                                                                                                                                                     
  Single ventricle                          Fixler et al^21^     286                                                        64.7 (58.8--69.9)                                            56.1 (49.9--61.7)                                                                                                                                                                                                                            
  Garne^23^                                 16                                                                              56.3 (29.9-- 80.2)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                 
  Moons et al^28^                           9                    56 (21--86)[a](#jah31455-note-0102){ref-type="fn"}         55.6 (21.2--86.3)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Tennant et al^32^                         31                   83.9 (65.5--93.0)                                          74.2 (55.0--86.2)                                            74.2 (55.0--86.2)                                           64.5 (43.1--80.0)                                                                                                                                                                
  Pooled estimate (95% CI)                  70.4 (54.1--84.4)    59.8 (50.4--68.8)                                                                                                                                                                                                                                                                                                                                                    
  *69.5 (63.3*--*75.3)*                                                                                                                                                                                                                                                                                                                                                                                                               
  Heterogeneity I^2^ & *P*‐value            65.0%, *P*=0.057     26.9%, *P*=0.250                                                                                                                                                                                                                                                                                                                                                     
  Ebstein\'s anomaly                        Garne^23^            5                                                                                                                       60.0 (14.7--94.7)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                     
  Moons et al^28^                           3                                                                               100 (29.2--100.0)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Nembhard et al^29^                        160                                                                             68.8 (61.0--75.8)[a](#jah31455-note-0102){ref-type="fn"}                                                                                                                                                                                                                                                  
  Samanek et al^31^                         22                   67.9 (50.2--86.5)                                          64.3 (46.2--82.4)                                            64.3(46.2--82.4)                                            64.3(46.2--82.4)                                                                                                                                                                 
  Tennant et al^32^                         55                   67.3 (53.2--78.0)                                          58.0 (43.8--69.7)                                            58.0 (43.8--69.7)                                           54.6 (39.7--67.2)                                          54.6 (39.7--67.2)                                                                                                     
  Pooled estimate (95% CI)                                       65.6 (57.5--73.2)                                                                                                                                                                                                                                                                                                                                                    
  Heterogeneity I^2^ & *P*‐value                                 18.0%, *P*=0.300                                                                                                                                                                                                                                                                                                                                                     

Pooled estimated are calculated using random effects meta‐analysis. But where there are ≤3 studies, pooled estimates are also calculated using fixed effects meta‐analysis with these results being shown in italics. AVA/S in Wang et al\'s studies refers to aortic valve stenosis only. IVS indicates intact ventricular septum; VSD, ventricular septal defect.

Indicates that 95% CIs were not reported in the study, but 95% binomial exact 95% CIs were calculated by the authors.

95% CIs obtained from author

John Wiley & Sons, Ltd

For subtypes for which just 3 studies reported survival, pooled estimates were also calculated using fixed‐effect meta‐analysis (Table [2](#jah31455-tbl-0002){ref-type="table-wrap"}). Pooled survival estimates were generally similar for the random‐ and fixed‐effects models, with the exception of the 10‐ and 15‐year pooled estimates for common arterial trunk (28.9% versus 35.4% and 36.5% versus 54.4%, respectively).

Quality Appraisal {#jah31455-sec-0015}
-----------------

Quality appraisal is shown in Table [3](#jah31455-tbl-0003){ref-type="table-wrap"}. All articles satisfied the study ascertainment domain because, by definition, population‐based studies are representative of the population. The attrition domain was satisfied by 31% of articles because of studies failing to report the proportion of untraced cases; however, many of the studies classed unmatched cases as alive, so it is possible that all cases were traced. The outcome ascertainment domain was satisfied by 94% of studies, and the analysis domain was satisfied by 81%. Studies that did not satisfy the analysis domain were those that did not perform survival analysis and instead reported the proportion alive, which does not account for case censorship. This may have slightly inflated survival in these studies.

###### 

Quality Appraisal of Included Articles

  Domain                                                                                                                                                                Quality Items, Potential Bias                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Yes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Not Stated                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Number of Studies, %
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------
  Study ascertainment                                                                                                                                                   The study population is adequately described for key characteristics (ie, CHD subtype frequency, sex distribution, ethnicity)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [21](#jah31455-bib-0021){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}                                                                                                                                                                                                                     [20](#jah31455-bib-0020){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  9 (56%)
  Ascertainment is adequately described, including method of ascertainment included birth years, study location                                                         [20](#jah31455-bib-0020){ref-type="ref"}, [21](#jah31455-bib-0021){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 16 (100%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Inclusion and exclusion criteria are adequately described (ie, ICD codes stated and inclusion of extracardiac anomalies                                               [21](#jah31455-bib-0021){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                 [20](#jah31455-bib-0020){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        13 (81%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  There is adequate ascertainment                                                                                                                                       [20](#jah31455-bib-0020){ref-type="ref"}, [21](#jah31455-bib-0021){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 16 (100%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  POTENTIAL BIAS: The study sample represents the population of interest on key characteristics sufficient to limit potential bias to the results                       [20](#jah31455-bib-0020){ref-type="ref"}, [21](#jah31455-bib-0021){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 16 (100%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Study attrition                                                                                                                                                       The proportion of traced cases is stated and adequate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            [20](#jah31455-bib-0020){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              [21](#jah31455-bib-0021){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}   5 (31%)
  Reasons for untraced cases are provided                                                                                                                               [20](#jah31455-bib-0020){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           [22](#jah31455-bib-0022){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     [21](#jah31455-bib-0021){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                                                                                                     4 (25%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Untraced cases are adequately described for key characteristics (ie, CHD subtype)                                                                                     [20](#jah31455-bib-0020){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              [21](#jah31455-bib-0021){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                                                                                                     5 (31%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  There are no important differences between key characteristics and outcomes in participants who were traced and untraced                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            [20](#jah31455-bib-0020){ref-type="ref"}, [21](#jah31455-bib-0021){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}   0 (0%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  POTENTIAL BIAS: Untraced cases are not associated with key characteristics (ie, the study data adequately represent the sample), sufficient to limit potential bias   [20](#jah31455-bib-0020){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              [21](#jah31455-bib-0021){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                                                                                                     5 (31%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Outcome ascertainment                                                                                                                                                 Frequency of outcome is recorded                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 [20](#jah31455-bib-0020){ref-type="ref"}, [21](#jah31455-bib-0021){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}   [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              14 (88%)
  The method of ascertainment of deaths is valid and reliable to limit misclassification bias                                                                           [20](#jah31455-bib-0020){ref-type="ref"}, [21](#jah31455-bib-0021){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                [25](#jah31455-bib-0025){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         15 (94%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  POTENTIAL BIAS: The outcome of interest is adequately measured in study participants to sufficiently limit potential bias                                             [20](#jah31455-bib-0020){ref-type="ref"}, [21](#jah31455-bib-0021){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                [25](#jah31455-bib-0025){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         15 (94%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Analysis                                                                                                                                                              There is sufficient presentation of results (ie, number of cases and 95% CIs)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    [21](#jah31455-bib-0021){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                 [20](#jah31455-bib-0020){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      11 (69%)
  The analysis is adequate for the design of the study                                                                                                                  [20](#jah31455-bib-0020){ref-type="ref"}, [21](#jah31455-bib-0021){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                 [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  13 (81%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Results are not selectively reported                                                                                                                                  [20](#jah31455-bib-0020){ref-type="ref"}, [21](#jah31455-bib-0021){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 16 (100%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  POTENTIAL BIAS: The statistical analysis is appropriate for the design of the study, limiting potential for presentation of invalid results                           [20](#jah31455-bib-0020){ref-type="ref"}, [21](#jah31455-bib-0021){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [32](#jah31455-bib-0032){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}, [35](#jah31455-bib-0035){ref-type="ref"}                                                                                                                                 [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  13 (81%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

CHD indicates congenital heart disease; ICD, International Classification of Disease.
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Discussion {#jah31455-sec-0016}
==========

In this systematic review and meta‐analysis, we found that 87.0% of individuals born with CHD survived to age 1 year, 85.4% survived to age 5 years, and 81.4% survived to age 10 years. Few studies reported survival beyond age 10 years, but survival appeared to continue to gradually decrease into adulthood. There was substantial variation in survival estimates among articles, some of which was accounted for by study period, which positively affected survival.

The main strength of this systematic review is its restriction to population‐based studies. Although including hospital‐based studies would have increased the amount of data available, such studies underascertain milder CHD subtypes that do not require major medical intervention. In addition, children with severe CHD may travel to centers with specialist expertise; therefore, the survival estimates reported by hospital‐based studies can be unrepresentative of the general population of individuals with CHD. The robustness of the individual rates of bias was examined using a quality assessment with previously published domains and items.[19](#jah31455-bib-0019){ref-type="ref"} Although each study failed to satisfy at least 1 quality item because of the population‐based study designs, the potential for bias in each domain remained low. Moreover, for all CHD, we did not identify any significant publication bias according to the Egger test.

A further strength is the comprehensive nature of our search strategy. Three databases were searched for relevant citations, along with key journals and reference lists; therefore, the likelihood of missing key studies was limited. Full articles were reviewed by both authors to ensure that they fully met the inclusion criteria and that data were extracted correctly. A further strength is that we reported pooled estimates calculated from fixed‐ and random‐effects meta‐analyses if there were just 3 studies reporting survival. Random‐effects meta‐analysis may calculate pooled estimates using an imprecise between‐study variance if the number of studies is low.[15](#jah31455-bib-0015){ref-type="ref"} The pooled estimates from the fixed‐effect meta‐analyses were broadly similar to those from the random‐effects meta‐analyses but with smaller confidence intervals.

There were also several limitations. The maximum follow‐up was just 30 years, with 5 of the included studies reporting survival to just 5 years. The greatest risk of death occurred in infancy, but survival continued to decrease over follow‐up, although at a much lesser rate. A study of CHD‐related mortality rates between 1999 and 2006 in the United States showed a high mortality rate of 41.5 per 100 000 in infancy, which decreased to 1.38 between ages 1 and 4 years and stabilized at ≈0.55 between the ages of 5 and 65 years. After age 65 years, the mortality rate doubled to 1.10 per 100 000.[36](#jah31455-bib-0036){ref-type="ref"}

A further limitation is that longer term survival estimates may not be representative of children born with CHD today. Even in the most recent studies, 25‐year survival rates related to persons born in the 1990s; in our metaregression of 1‐, 5‐, and 10‐year survival, we showed that survival estimates improved over time.

All included studies were performed in high‐income Western populations. Evidence suggests that infant mortality rates associated with congenital anomalies are greater in low‐income countries.[37](#jah31455-bib-0037){ref-type="ref"} Consequently, the survival estimates in this review are not likely to be globally representative. Although we included only articles written in the English language, we did not identify any relevant articles written in other languages.

Most of the included articles included cases with extracardiac anomalies[20](#jah31455-bib-0020){ref-type="ref"}, [21](#jah31455-bib-0021){ref-type="ref"}, [22](#jah31455-bib-0022){ref-type="ref"}, [23](#jah31455-bib-0023){ref-type="ref"}, [24](#jah31455-bib-0024){ref-type="ref"}, [25](#jah31455-bib-0025){ref-type="ref"}, [26](#jah31455-bib-0026){ref-type="ref"}, [27](#jah31455-bib-0027){ref-type="ref"}, [28](#jah31455-bib-0028){ref-type="ref"}, [29](#jah31455-bib-0029){ref-type="ref"}, [30](#jah31455-bib-0030){ref-type="ref"}, [31](#jah31455-bib-0031){ref-type="ref"}, [33](#jah31455-bib-0033){ref-type="ref"}, [34](#jah31455-bib-0034){ref-type="ref"}; therefore, it is difficult to assess how much of the mortality was accounted for by CHD as opposed to the co‐occurring congenital anomalies. Nevertheless, cases with extracardiac anomalies accounted for only 20% of cases, and some extracardiac anomalies were not likely to be life threatening; therefore, the impact on survival is likely to be low. All articles used all‐cause mortality, meaning that deaths may not have been directly related to the CHD diagnosis.

Although this review provides insight into long‐term mortality associated with CHD, we did not account for morbidity. Research suggests that quality of life is lower in those with CHD and that those who live with CHD can have morbidities such as endocarditis, cerebrovascular accidents, myocardial infarctions, and arrhythmias.[38](#jah31455-bib-0038){ref-type="ref"}, [39](#jah31455-bib-0039){ref-type="ref"}, [40](#jah31455-bib-0040){ref-type="ref"} The American Heart Association has also reported that children with CHD are at increased risk of developmental disorders.[41](#jah31455-bib-0041){ref-type="ref"} Research suggests that children with CHD are more likely to require special education services, regardless of CHD severity.[42](#jah31455-bib-0042){ref-type="ref"}

In our metaregression, we found that a more recent study period positively affected survival estimates; however, even after adjustment for study period, there was still a high degree of heterogeneity. Although we adjusted for study period using the year of study commencement, the lengths of the study periods varied by article; therefore, our adjustment for the year of study commencement is not likely to have fully accounted for the changes in survival over time. Further heterogeneity is likely attributable to a variety of sources. Case ascertainment is likely a major cause. Olsen et al reported lower survival estimates even after accounting for study period, but their prevalence of CHD was almost half that of other studies. Given that they included only cases diagnosed before age 1 year, it is likely that they underascertained cases with milder CHD subtypes, such as ventricular septal defect.[30](#jah31455-bib-0030){ref-type="ref"} The data sources used may also have contributed to variation in ascertainment, with articles using hospital records as opposed to congenital anomaly registers (which use multiple sources for ascertainment) contributing to lower survival estimates, likely due to the milder cases being underascertained.[31](#jah31455-bib-0031){ref-type="ref"}

Variation in study periods is arguably the greatest source of heterogeneity for survival estimates. Survival has improved over time because of advances in surgical correction. The Fontan operation, for example, for repair of single ventricle, hypoplastic left heart, and tricuspid atresia and the conduit repair for cases of common arterial trunk were introduced in the late 1970s and developed throughout the 1980s and 1990s.[43](#jah31455-bib-0043){ref-type="ref"}, [44](#jah31455-bib-0044){ref-type="ref"} The arterial switch operation for treatment of transposition of the great vessels was introduced in 1975[45](#jah31455-bib-0045){ref-type="ref"} and fully replaced the atrial switch operations in the early 1990s, resulting in improved long‐term survival.[46](#jah31455-bib-0046){ref-type="ref"} Survival is also likely to have improved over time because of advances in prenatal diagnosis. Greater prenatal diagnosis rates may have led to an increase in rates of termination (for fetal anomaly). If cases with the more severe subtypes were terminated, this would have resulted in better survival. Prenatal diagnosis also allows quicker intervention at birth or even in utero, which may also improve survival.[47](#jah31455-bib-0047){ref-type="ref"} In addition, survival is likely to have improved because of the introduction of prostaglandin, which underwent trials in neonates with cyanotic CHD in the 1970s,[48](#jah31455-bib-0048){ref-type="ref"}, [49](#jah31455-bib-0049){ref-type="ref"} although it was not frequently administered until the 1980s.

The improvement in survival rates over time has led to an emerging population of adolescents and adults with CHD. These patients require long‐term follow‐up, sometimes leading to reinvestigation and reoperation. Consequently, population‐based surveillance of CHD is crucial to adequately assess the variety of health and social services required by those with CHD throughout their lives.
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